Protection for an unpredictable world

We are developing cutting-edge vaccines by utilizing our innovative adjuvant technology and  our expertise of Toll-like Receptor (TLR) biology to modulate the immune system.

TLR Biology

HEPLISAV-B®
[HEPATITIS B VACCINE (RECOMBINANT) ADJUVANTED]

Focusing on Developing Innovative Vaccines

Utilizing innovative adjuvant technology, Dynavax is leveraging Toll-like receptor (TLR) biology to stimulate the innate immune system to trigger a specific adaptive immune response to specific disease antigens for improved vaccines.

Recent News

View All News